ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2025 ANS Winter Conference & Expo
November 9–12, 2025
Washington, DC|Washington Hilton
Standards Program
The Standards Committee is responsible for the development and maintenance of voluntary consensus standards that address the design, analysis, and operation of components, systems, and facilities related to the application of nuclear science and technology. Find out What’s New, check out the Standards Store, or Get Involved today!
Latest Magazine Issues
Oct 2025
Jul 2025
Latest Journal Issues
Nuclear Science and Engineering
November 2025
Nuclear Technology
October 2025
Fusion Science and Technology
Latest News
Senate EPW Committee to hold Nieh nomination hearing
Nieh
The Senate Environment and Public Works Committee will hold a nomination hearing Wednesday for Ho Nieh, President Donald Trump’s nominee to serve as commission at the Nuclear Regulatory Commission.
Trump nominated Nieh on July 30 to serve as NRC commissioner the remainder of a term that will expire June 30, 2029, as Nuclear NewsWire previously reported.
Nieh has been vice president of regulatory affairs at Southern Nuclear since 2021, though since June 2024 he has been at the Institute of Nuclear Power Operations as a loaned executive.
A return to the NRC: If confirmed by the Senate, Nieh would be returning to the NRC after three previous stints totaling nearly 20 years.
Jisue Moon, Kristian Myhre, Hunter Andrews, Joanna McFarlane
Nuclear Technology | Volume 209 | Number 6 | June 2023 | Pages 787-808
Critical Review | doi.org/10.1080/00295450.2022.2158666
Articles are hosted by Taylor and Francis Online.
Technitium-99m (99mTc), a widely used radioisotope, is used in tens of millions of medical diagnostic procedures annually. However, it is hard to store and must be immediately used upon production due to its short half-life (i.e., 6 h); thus, it is currently produced from 99Mo, which itself is a result of 235U fission. The majority of 99Mo supplies to U.S. patients are currently provided by foreign producers and produced using highly enriched uranium (HEU). In order to minimize the proliferation risks of HEU-based medical isotope production, the U.S. Department of Energy’s National Nuclear Security Administration has funded a program to accelerate the development of technologies to produce 99Mo without the use of HEU.
Today, the global supply of 99Mo depends on a limited number of nuclear reactors, and production has been interrupted unexpectedly since 2009 due to the fleet’s advanced age. Alternative options for 99Mo production are discussed in this paper, and one potential option is to obtain 99mTc from molten salt reactors (MSRs). A MSR is a nuclear fission reactor that can operate at or close to atmospheric pressure with liquid fuel, which allows for producing isotopes in a timely manner. In this paper, the past and current production of 99Mo via nuclear reactors is described, and the future of 99Mo production by MSRs is discussed. The behavior and chemical properties of molybdenum in fluoride salts in MSRs and the possible extraction methods are also examined in addition to the limitation of current studies.
